Evaluation of ACEI Use on Kidney Function and Lipid Profile in Outpatient Hypertension Patients at Raden Mattaher General Hospital, Jambi, Jambi Province
DOI:
https://doi.org/10.35451/jfm.v9i1.3756Keywords:
ACEI, Kidney Function, Lipid ProfileAbstract
Hypertension is a global health problem that increases the risk of cardiovascular disease and impaired kidney function. The use of Angiotensin-Converting Enzyme Inhibitors (ACEIs) is widely recommended due to their effectiveness in lowering blood pressure and providing renoprotective effects. However, variations in therapeutic responses, particularly in kidney function and lipid profile, require further evaluation. This study aimed to analyze the association between ACEI use and kidney function and lipid profile in outpatient hypertensive patients. This study employed an observational analytic design with a retrospective approach based on medical record data of hypertensive patients receiving ACEI therapy. Samples were selected based on inclusion criteria, with complete data on kidney function (eGFR, serum creatinine, and BUN) and lipid profile (total cholesterol, LDL, HDL, and triglycerides). Data were analyzed using descriptive statistics and inferential analysis using the Kruskal–Wallis test. The results showed that the majority of patients were in the late elderly age group (56–65 years) (39.6%) and predominantly male (62.1%). significantly associated with serum creatinine (p = 0.000), while no significant associations were found with eGFR (p = 0.206) and BUN (p = 0.170). In addition, the duration of ACEI use showed no significant association with eGFR (p = 0.089), but was significantly associated with serum creatinine (p = 0.001) and BUN (p = 0.009). Regarding lipid profiles, both the type and duration of ACEI use were significantly associated with all parameters, including total cholesterol, LDL, HDL, and triglycerides (all p = 0.000). In conclusion, ACEI therapy shows differential associations with kidney function and lipid profile parameters in hypertensive patients. Therefore, regular monitoring of renal function and lipid profiles is recommended to optimize therapeutic outcomes and prevent potential metabolic and renal complications.
Downloads
References
1. Kaplan H., Taylor D., Olson S. Quinapril: Overview of preclinical data. Clin Cardiol. 1990;13:VII-6-VII–12.
2. Powers B, Greene L, Balfe L. Updates on the Treatment of Essential Hypertension: A Summary of AHRQ’s Comparative Effectiveness Review of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Direct Renin Inhibitors. J Manag Care Pharm. 2011;17(8):1–14.
3. Daoud NM, Qadi OA, Al-talhi DO, Al-sharabi HK. Diabetes and Clinical Research Effect of Antihypertensive Agents on Biochemical Parameters in Diabetic Patients in Taif - KSA. Int J Diabetes Clin Res. 2019;6(4):1–8.
4. Surdacki A. Effects of Atorvastatin Dose and Concomitant Use of Angiotensin-Converting Enzyme Inhibitors on Renal Function Changes over Time in Patients with Stable Coronary Artery Disease : A Prospective Observational Study. Int J Mol Sci. 2016;17(106):1–12.
5. Hesham D, Atyia AE morsey, Mahmood S, Addein S. Renoprotective Effect of Losartan Versus Enalapril in Children with Chronic Kidney Disease. J Adv Med Med Res. 2022;34(1):30–42.
6. Suling FRW. Hipertensi. Fakultas Kedokteran Universitas Kristen Indonesia. Jakarta: Fakultas Kedokteran Universitas Kristen Indonesia; 2021.
7. Carey RM, Muntner P, Bosworth HB, Whelton PK. Prevention and control of hypertension. J Am Coll Cardiol. 2022;79(20):e1–e32.
8. GBD 2023 Risk Factors Collaborators. Global burden of risk factors, 1990–2023. Lancet. 2023;402(10397):1788–1858.
9. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37.
10. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA hypertension guideline. Hypertension. 2018;71(6):e13–e115.
11. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence. Lancet. 2021;398(10304):957–80.
12. Sobhy M, Eletriby A, Ragy H, Kandil H, Ayman M, Nabil S. ACE Inhibitors and Angiotensin Receptor Blockers for the Primary and Secondary Prevention of Cardiovascular Outcomes : Recommendations from the 2024 Egyptian Cardiology Expert Consensus in Collaboration with the CVREP Foundation. Cardiol Ther [Internet]. 2024;13(4):707–36. Available from: https://doi.org/10.1007/s40119-024-00381-6
13. Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124–40.
14. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global guideline. Hypertension. 2020;75(6):1334–57.
15. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention. Eur Heart J. 2021;42(34):3227–3337.
16. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for hypertension. Eur Heart J. 2018;39(33):3021–104.
17. Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Pathophysiology and management. J Am Soc Nephrol. 2024;35(1):12–25.
18. Sarafidis PA. Hypertension and kidney disease. Lancet Diabetes Endocrinol. 2024;12(1):45–58.
19. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: A review. JAMA. 2024;331(2):129–40.
20. Fu EL, Clase CM, Evans M, Lindholm B, Rotmans JI, Dekker FW, et al. Comparative effectiveness of renin–angiotensin system inhibitors. Lancet. 2024;403(10425):123–34.
21. Heerspink HJL, Stefánsson B V, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Renal outcomes with RAAS inhibition. N Engl J Med. 2023;389(2):143–54.
22. Sarafidis P. Use of ACEi / ARBs , SGLT2 inhibitors and MRAs can help us reach the therapeutic ceiling in CKD PROGRESSION : THE CORNERSTONE OF. Clin Kidney J [Internet]. 2024;17(2):1–8. Available from: https://doi.org/10.1093/ckj/sfae014
23. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–e646.
24. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2024;38(32):2459–72.
25. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC guideline on cholesterol management. Circulation. 2019;139(25):e1082–e1143.
26. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L. ESC/EAS guidelines for dyslipidemia management. Eur Heart J. 2020;41(1):111–88.
27. Toth PP, Fazio S, Wong ND, Hull M, Nichols GA. Risk of cardiovascular events with lipid abnormalities. J Clin Lipidol. 2022;16(2):123–35.
28. Ku E, Inker LA, Tighiouart H, McCulloch CE, Adingwupu OM, Greene T, et al. Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease: A Systematic Review and Retrospective Individual Participant–Level Meta-analysis of Clinical Trials. Ann Intern Med. 2024;177(7).
29. Kang E, Han M, Kim H, Lee J. Effects of ACE inhibitors on renal outcomes. Kidney Int. 2024;105(1):45–56.
30. Chen X, Li Y, Zhang H. Quality of life and associated factors in patients with chronic kidney disease undergoing hemodialysis: A multicenter study. BMC Nephrol. 2024;56(2):345–356.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Onesis Novita Dewi, Diana Laila Ramatillah, Kashif Ullah Khan, Ida Paulina Sormin
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright in each article is the property of the Author.
